Addressing unmet medical needs in type 2 diabetes: A narrative review of drugs under development

Current Diabetes Reviews

Volumn 11, Issue 1, 2015, Pages 17-31

  Mittermayer, Friedrich ^a   Caveney, Erica ^a   De Oliveira, Claudia ^a   Gourgiotis, Loukas ^a   Puri, Mala ^a   Tai, Li Jung ^a   Turner, J Rick ^a  

^a IQVIA   (United States)

Author keywords

Antidiabetic drugs; New characteristics; New drug development; New insulins; New mechanisms of action; Personalized medicine; Type 2 diabetes

Indexed keywords

ANTIINFLAMMATORY AGENT; APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; G PROTEIN COUPLED RECEPTOR AGONIST; GASTROINTESTINAL PEPTIDE AGONIST; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR ANTAGONIST; GLUCOKINASE; GLUCOKINASE ACTIVATOR; INSULIN; INTERLEUKIN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; SODIUM GLUCOSE COTRANSPORTER 1 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; AGONISTS; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG DESIGN; GLUCOSE BLOOD LEVEL; NEEDS ASSESSMENT;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEEDS ASSESSMENT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84926308686     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666141224121927     Document Type: Article

References (138)

1. American Diabetes Association web site. Available at: http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav (Accessed 27th June 2014).
2. [2] Dabelea D, Mayer-Davis EJ, Saydah S, et al. SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311: 1778-86.
3. [No authors listed] American Diabetes Association. Scientific Statement. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1033-46.
4. International Diabetes Federation. IDF Diabetes Atlas, 6th Edition. Available at: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf (Accessed 09 June 2014)
5. [5] European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. May 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (Accessed 27 June 2014)
6. [6] DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36(Suppl 2): S127-38.
7. [7] Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
8. [8] UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
9. [9] Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
10. [10] Diabetes in the UK 2010: Key statistics on diabetes. March 2010. Available at: http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf (Accessed 23 August 2014)
11. [11] Egan AE, Blind E, Dunder K et al. Pancreatic safety of incretinbased drugs—FDA and EMA Assessment. N Engl J Med 2014; 370: 794-7.
12. [12] American Diabetes Association Position Statement. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37(Suppl 1); S14-S80. Available at: http://care.diabetesjournals.org/content/37/Supplement_1/S14.full.pdf+html (Accessed 23 August 2014)
13. [13] Inagaki N, Onouchi H, Sano H, et al. SYR-472, a novel onceweekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 125-32.
14. Baughman R, Costello D, Marino M, et al. Inhaled GLP-1 and exenatide: different effects on pancreatic and gastric activity. Scientific Sessions of the American Diabetes Association; New Orleans, Louisiana, USA, 2009. p. 160-OR.
15. [15] Rohloff CM, Alessi TR, Yang B, et al. DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008; 2: 461-7.
16. [16] Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140-7.
17. [17] Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522-8.
18. [18] Steiner S, Hompesch M, Pohl R, et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008; 51: 1602-6.
19. [19] Taylor R, Magnusson I, Rothman DL, et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 1996; 97: 126-32.
20. [20] Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R. Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 2002; 283: E275-83.
21. [21] Khedkar A, Iyer H, Anand A, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab 2010; 12: 659-64.
22. [22] Eldor R, Arbit E, Corcos A, Kidron M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One 2013; 8: e59524.
23. [23] Zisser H, Jovanovic L, Markova K, et al. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012; 14: 997-1001.
24. MannKind. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes 2013. Available at: http://www.investors.mannkindcorp.com/phoenix.zhtml?c=147953&p=irol-newsArticle&ID=1197424&highlight= (Accessed 23 August 2014)
25. [25] Barish GD, Evans RM. PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 2004; 15: 158-65.
26. [26] DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL; INT131-007 Study Group. Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 2014; 37: 1918-23.
27. Adamed Group. Publications. Available at: http://www.adamed.com.pl/en/r-d/publications/new-phenylpropanoic-acid-derivativewith-antidiabetic-potential-acting-as-a-partial-ppar-gamma-agonistpreclinical-studies/(Accessed October 12 2014)
28. Wellstat Therapautics Corporation. Wellstat Therapeutics and Sanofi-aventis Enter Agreement On Novel Therapy for Type II Diabetes. Available at: http://www.wellstattherapeutics.com/therapeutics/WT_SA_Press_Release_21_Oct_09.pdf (Accessed 12 October 2014)
29. [29] Henriksen K, Byrjalsen I, Qvist P, et al. BALLET Trial Investigators. Efficacy and safety of the PPAR-γ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. Diabetes Metab Res Rev 2011; 27: 392-401.
30. [30] Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR. Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPAR-γ and GLUT4 expression. Int J Gen Med 2011; 4: 345-357.
31. [31] Xu C, Wang LL, Liu HY, et al. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism. Acta Pharmacol Sin 2006; 27: 223-8.
32. [32] Zhang N, Chen W, Zhou X, et al. C333H ameliorated insulin resistance through selectively modulating peroxisome proliferatoractivated receptor γ in brown adipose tissue of db/db mice. Biol Pharm Bull 2013; 36: 980-7.
33. [33] Yamanaka, M, Ishikawa, T, Cgriep, A, Axt, D, Heneka, M. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci 2012; 32: 17321-31.
34. [34] Kim SG, Kim DM, Woo JT, et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. PLoS One 2014; 9: e92843.
35. Tsunoda, M, Kobayashi, N, Utsumi, M, et al. KRP-101: A Potent PPAR-α ± agonist ameliolates fat-induced insulin resistance with suppression of adiposity in dogs. Diabetes 2007; 56(S1): p A137.
36. [36] Kyorin Pharmaceuticals web site. Products under development, 13th May 2009. Available at: http://www.kyorin-gr.co.jp/en/ir/pdf/ar09/AR2009E12.pdf (Accessed 3rd November 2014)
37. [37] Cariou B, Zaïr Y, Staels B, Bruckert E. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011; 34: 2008-14.
38. [38] Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013; 36: 2923-30.
39. [39] Delmedico MK, Severynse-Stevens D, Oliver WR, et al. DB959 is a novel, dual PPAR α/δ agonist which controls glucose and regulates triglycerides and HDLc in animal models of T2D and dyslipidemia. 69th Annual Scientific Sessions of the American Diabetes Association. Abstr. 365-OR, 5 Jun 2009.
40. DARA BioSciences. Press Release: DARA BioSciences Grants T3D Therapeutics Exclusive Worldwide Rights to Develop and Commercialize DB959. Available at: http://ir.darabio.com/pressreleases/detail/134/dara-biosciences-grants-t3d-therapeuticsexclusive-worldwide-rights-to-develop-and-commercialize-db959 (Accessed 12 October 2014)
41. [41] Sahebkar A, Chew GT, Watts GF. New peroxisome proliferatoractivated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014; 15: 493-503.
42. [42] Iwaisako K, Haimerl M, Paik YH, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012; 109: E1369-76.
43. [43] Fedorova LV, Komal Sodhi K, Cara Gatto-Weis C, et al. Peroxisome proliferator-activated receptor δ agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS One 2013; 8: e64436.
44. [44] Li P-P, Shan S, Chen Y-T, Ning Z-Q, Sun S-J. The PPAR-α/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Brit J Pharmacol 2006; 148: 610-8.
45. [45] He BK, Ning ZQ, Li ZB, et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Research. 2012; 2012: 546548.
46. http://bi.adisinsight.com/RDI/ViewMediaRelease.aspx?render=view&adnm=809111087
47. [47] Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55: 1-12.
48. [48] Matschinsky FM, Zelent B, Doliba NM, et al. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 2011; (203): 357-401.
49. [49] Rees MG, Gloyn AL Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour? Br J Pharmacol 2013; 168: 335-8.
50. [50] De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013; 168: 339-53.
51. [51] Sarabu R, Bizzarro FT, Corbett WL, et al. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients. J Med Chem 2012; 55: 7021-36.
52. [52] Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010; 95: 5028-36.
53. [53] Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2560-6.
54. [54] Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013; 15: 750-9.
55. [55] Pfefferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 2013; 8: 319-30.
56. [56] Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 2013; 34: 90-9.
57. [57] Stevens BD, Litchfield J, Pfefferkorn JA, et al. Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia. Bioorg Med Chem Lett 2013; 23: 6588-92.
58. [58] D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011; 13 (Suppl 1): 126-32.
59. [59] Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290: 839-43.
60. [60] Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003; 100: 1438-43.
61. [61] Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-24.
62. ISIS Pharmaceuticals. Press releases dated 14th May and 16th June, 2014. Available at: http://www.isispharm.com/index.htm (Accessed 17th June, 2014).
63. [63] Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009; 296: E415-21.
64. [64] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
65. [65] Hou, C, Sui, Z. (2012).CCR2 antagonists for the treatment of diseases associated with inflammation. In J. Levin & S. Laufer (Eds.), 2012. Anti-inflammatory drug discovery (pp. 350-90). Boston, MA: The Royal Society of Chemistry.
66. [66] Dinarello, CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-32.
67. [67] Ridker PM, Howard CP, Walter V, et al. CANTOS Pilot Investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-48.
68. [68] Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab 2013; 39: 524-31.
69. CANTOS. Canakinumab Anti-inflammatory Thrombosis Outcomes Study. Available at: http://www.thecantos.org/ (Accessed 12 October 2014)
70. [70] Sloan-Lancaster J, Abu-Raddad E, Polzer J, et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 2013; 36: 2239-46.
71. XBiotech. XBiotech Reports Positive Phase I Interim Analysis Results from Type 2 Diabetes Study. Available at: http://www.xbiotech.com/about/news/xbiotech-reports-positive-phasetwo-interim-analysis-results-from-type-2-diabetes-study.html (Accessed 12 October 2014).
72. [72] Bharate SB, Nemmani KV, Vishwakarma RA. Progress in the discovery and development of small-molecule modulators of Gprotein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin Ther Pat 2009; 19: 237-642012.
73. [73] Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-11.
74. Miller AR, Cox A, Briere D, et al. LY2881835: a potent, efficacious and selective GPR40 agonist stimulates insulin and GLP-1 secretion normalising glucose levels in preclinical models of type 2 diabetes. EASD Berlin. 1-5 October 2012. Presentation 547.
75. [75] Toda N, Hao X, Ogawa Y et al. Potent and orally bioavailable GPR142 agonists as novel insulin secretagogues for the treatment of type 2 diabetes. ACS Med Chem Lett 2013; 4: 790-4.
76. Takeda web site. Takeda Announces Termination of Fasiglifam (TAK-875) Development. Press release, 27th December 2013. Available at: http://www.takeda.com/news/2013/20131227_6117.html (Accessed 27 October 2014)
77. [77] Alquier T, Poitout V. GPR40: Good cop, bad cop? Diabetes 2009; 58: 1035-6.
78. [78] Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011; 152: 374-83.
79. [79] Overton HA, Fyfe MCT, Reynet C. GPR119, a novel G proteincoupled receptor target for the treatment of type 2 diabetes and obesity. Brit J Pharmacol 2008; 153: S76–81.
80. [80] Zhu X, Huang W, Qian H. GPR119 agonists: a novel strategy for type 2 diabetes treatment. In Diabetes Mellitus–Insights and Perspectives. 4-Editor Oluwafemi O. Oguntibeju, In Tech, China 2013; pp. 59-82.
81. [81] Nunez DJ, Bush MA, Collins DA, et al. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS One 2014; 9: e92494.
82. [82] Dobbins RL, Shearn SP, Byerly RL, et al. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 1013-21.
83. [83] Ross SA, Dzida G, Vora J, et al. Impact of weight gain on outcomes in type 2 diabetes. Current Med Res Opin 2011; 27: 1431-8.
84. [84] Inzucchi SE, Bergenstal RM, Buse JB, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
85. [85] Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-56.e5.
86. [86] Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a doubleblind, randomized, controlled trial. Diabetes 2005; 54: 2390-5.
87. [87] Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729-36.
88. [88] Day JW, Gelfanov V, Smiley D, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012; 98: 443-50.
89. [89] Patel V, Joharapurkar A, Dhanesha N, et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol 2013; 91: 1009-15.
90. [90] Parthier C, Kleinschmidt M, Neumann P, et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci USA 2007; 104: 13942-7.
91. [91] Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-4.
92. [92] Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367-75.
93. [93] Jordon J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008; 83: 281-7.
94. [94] Bhat VK, Kerr, BD, Vasu S, Flatt PR, Gault VA. A DPP-IVresistant triple-acting agonist of GIP, GlP-1, and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia 2013; 56: 1417-24.
95. [95] Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
96. [96] Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40.
97. [97] Plaisancié P, Dumoulin V, Chayvialle JA, Cuber JC. Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 1995; 145: 521-6.
98. [98] Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC. Peptide YY, Glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 1998; 139: 3780-6.
99. [99] Adrian TE, Ballantyne GH, Longo WE, et al. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 1993; 34: 1219-24.
100. [100] Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr Med Chem 2006; 13: 997-1016.
101. [101] Wu Y, Aquino CJ, Cowan DJ, et al. Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem 2013; 56: 5094-114.
102. [102] Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2011; 2: 133-45.
103. [103] Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158-69.
104. Rosenstock J, Cefalu WT, Lapuerta P, et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of sodium glucose transporters SGLT1 and SGLT2, in type 2 diabetes on metformin monotherapy. Diabetes Care 2014 Sep 11 [Epub ahead of print]
105. [105] Pereira CD, Azevedo I, Monteiro R, Martins MJ. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 869-81.
106. [106] Hollis G, Huber R. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13: 1-6.
107. [107] Morton NM, Holmes MC, Fiévet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001; 276: 41293-300
108. [108] Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem 2008; 8: 702-10.
109. [109] Courtney R, Stewart PM, Toh M, et al. Modulation of 11betahydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab 2008; 93: 550-6.
110. [110] Rosenstock J, Banarer S, Fonseca VA, et al. INCB13739-202 Principal Investigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010; 33: 1516-22.
111. [111] Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab 2011; 13: 498-504.
112. [112] Walker BR. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs 2013; 73: 1385-93.
113. [113] Maciejewski BS, LaPerle JL, Chen D, et al. Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans. Am J Physiol Gastrointest Liver Physiol 2013; 304: G958-69.
114. [114] Di Marzo V, Piscitelli F, Mechoulam R. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol 2011; (203): 75-104.
115. [115] Conti R, Mannucci E, Pessotto P, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes 2011; 60: 644-651.
116. [116] Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333-40.
117. [117] Iglesias P, Selgas R, Romero S, Díez JJ. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 2012; 167: 301-9.
118. [118] Zinker B, Mika A, Nguyen P, et al. Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance. Metabolism 2007; 56: 380-7.
119. [119] Kolonics A, Literati-Nagy P, Peitl B, et al., editors. BGP-15, a New Type of Insulin Sensitizer. 66th Scientific Sessions of the American Diabetes Association; 2006; Washington DC, USA.
120. [120] Kievit P, Halem H, Marks DL, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes 2013; 62: 490-7.
121. [121] Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012; 14: 852-8.
122. [122] Fouqueray PL, Pirags V, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013; 36: 565-8.
123. [123] Panzhinskiy E, Ren J, Nair S. Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus. Curr Med Chem 2013; 20: 2609-25.
124. [124] Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 2013; 37: 15-25.
125. [125] Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103.
126. [126] Heiman M, Burton JH, Deych E, Shannon WD, Greenway FL. Improved oral glucose tolerance in prediabetics and type 2 diabetics in a pilot clinical trial testing a novel gastrointestinal microbiome modulator. OR40-5, Abstract 14546, at ICE/ENDO 2014.
127. [127] Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003; 26: 1408-12.
128. [128] Bauer S, Nauck MA. Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines—a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problems. Diabet Med 2014; 31: 78-1085.
129. [129] McCrate F, Godwin M, Murphy L. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes. A study of primary care practices in St John’s, Nfl., Can Fam Physician 2010; 56: e13-9.
130. [130] Gale EA. Is type 2 diabetes a category error? Lancet 2013; 381: 1956-7.
131. [131] Badalian-Very G. Personalized medicine in hematology-A landmark from bench to bed. Comput Struct Biotechnol J 2014; 10: 70-7.
132. [132] Nguyen KS, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014; 5: 576-87.
133. [133] Arnedos M, Soria JC, Andre F, Tursz T. Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat Rev 2014; 40: 1192-8.
134. [134] Woodcock J. The prospects for “personalized medicine” in drug development and drug therapy. Clin Pharmacol Ther 2007; 81: 164-9.
135. [135] Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366: 489-91.
136. [136] Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 2013; 36: 1779-88.
137. [No authors listed] ESH Hypertension Excellence Centres: a new strategy to combat an old foe. Blood Press 2007; 16: 276-7.
138. [138] White WB, Kostis JB. Leadership message. American Society of Hypertension-designated centers of excellence: a new initiative. J Clin Hypertens (Greenwich) 2011; 13: 391-2.